bims-tremyl Biomed News
on Therapy resistance biology in myeloid leukemia
Issue of 2026–11–15
25 papers selected by
Paolo Gallipoli, Barts Cancer Institute, Queen Mary University of London



  1. Blood. 2026 Nov 13. pii: blood.2026035348. [Epub ahead of print]
      Variability in how clinical trial elements are reported can hinder accurate interpretation and comparison of trial results. Here, we systematically analyzed published manuscripts of therapeutic clinical trials in myelodysplastic syndromes/neoplasms (MDS) focusing on how key data elements were reported and made recommendations on how to improve this reporting. We included peer-reviewed full text manuscripts that reported results of clinical trials in MDS and were published between January 1, 2015 to December 31, 2024. We analyzed the presence or absence of several pre-determined key reporting elements and then synthesized these data to evaluate for consistency across manuscripts. We identified substantial variability in descriptions of patient characteristics, as well as the definitions used for response criteria. For example, baseline ANC was reported in only 16% of lower-risk MDS studies and 23% of higher-risk MDS studies, while baseline bone marrow blast percentage was reported in only 55% of higher-risk MDS manuscripts. In addition, response endpoints lacked standardization, with six unique definitions of RBC transfusion independence identified in lower-risk MDS trials and seven different definitions of overall response rate identified in higher-risk MDS trials. Informed by the results of this analysis, we then performed a modified-Delphi process for members of the International Consortium for MDS (icMDS) to develop consensus-based recommendations for consistent and accurate reporting of MDS clinical trial results. We advocate that these recommendations serve as benchmarks and templates for clinical trial reporting in MDS to improve interpretability and comparison of results.
    DOI:  https://doi.org/10.1182/blood.2026035348
  2. Leukemia. 2026 Nov 11.
      Acute myeloid leukemia (AML) is a heterogeneous and aggressive hematologic malignancy associated with poor survival despite recent therapeutic advances. To identify novel anti-leukemic agents, we performed a high-throughput viability screen of 10,000 small molecules across 56 genetically diverse primary AML samples. Compounds with similar activity profiles were grouped into Compound Correlation Clusters (CCCs), leading to the identification of CCC163, which includes AML874, as a potent and selective hit. Integrated pharmacological and CRISPR-Cas9 approaches identified the Mediator complex as the molecular target of AML874. We demonstrated that AML874 acts as a selective CDK8/CDK19 inhibitor, disrupting Mediator-dependent transcription. FLT3-mutated AML showed increased sensitivity to AML874, suggesting a subtype-specific vulnerability. Notably, CDK8 inhibition synergized with venetoclax in AML cell lines and patient-derived xenograft models, resulting in enhanced anti-leukemic activity in vivo. Collectively, these findings establish CDK8/CDK19 inhibition as a therapeutically relevant strategy in AML.
    DOI:  https://doi.org/10.1038/s41375-026-03173-0
  3. Am J Hematol. 2026 Nov 07.
      BCOR and BCORL1 (BCOR/L1) mutations are observed in both myeloid neoplasms (MN) and bone marrow failure syndromes (BMF), but their clinical significance may differ. We analyzed 11 340 patients and identified 418 BCOR/L1-mutated patients, focusing on differences between MN and BMF. Compared with MN, BMF was associated with younger age, a higher frequency of normal karyotype, a greater proportion of missense mutations, and significantly lower variant allele frequencies (VAFs). We next compared BCOR/L1-mutated cases with wild-type cases. In MN, BCOR/L1 mutations were associated with older age, inferior survival, and a higher number of co-occurring mutations, whereas in BMF, they were associated with a higher prevalence of PNH clones. Single-cell DNA sequencing and VAF-based analysis demonstrated that BCOR/L1 mutations were usually secondary in MN but primary events in BMF. Longitudinal sequencing revealed that BCOR/L1-mutant clones often contracted or disappeared over time, even in progression, suggesting limited clonal fitness of BCOR/L1 mutations themselves; instead, progression was associated with increased mutational burden, particularly in RUNX1. Prognostically, BCOR/L1 mutations were associated with inferior survival in MN, whereas in BMF they were not associated with prognosis and tended to correlate with a favorable response to immunosuppressive therapy. RNA-sequencing analyses showed reduced BCOR/L1 expression in BMF, and BCOR knockout was associated with reduced HLA class I expression. Our findings suggest that BCOR/L1 mutations are secondary events in MN and co-occurring mutations may influence disease progression and prognosis, whereas in BMF they appear to be ancestral events acquired independently of progression to MN, potentially through immune privilege-related mechanisms.
    Keywords:   BCOR ; BCORL1 ; acute myeloid leukemia; aplastic anemia; myelodysplastic syndromes
    DOI:  https://doi.org/10.1002/ajh.70542
  4. Leukemia. 2026 Nov 09.
      Myelodysplastic neoplasms (MDS) are clonal hematopoietic stem cell disorders that frequently progress to secondary acute myeloid leukemia (sAML). Besides intrinsic genetic changes, the disease's development is heavily influenced by the bone marrow (BM) microenvironment, especially mesenchymal stromal cells (MSCs). In this study, we present a comprehensive characterization of how unhealthy MSCs affect natural killer (NK) cell anti-leukemic function in MDS and sAML. Using integrated ATAC-seq and RNA-seq profiling, we show that MDS/sAML-derived MSCs induce profound chromatin remodeling in NK cells, marked by reduced promoter accessibility and downregulation of genes essential for stress response and survival. Functionally, pathological MSCs fail to deliver the protective support normally provided by healthy MSCs, instead driving mitochondrial fragmentation and apoptosis in NK cells, ultimately suppressing their cytotoxic activity. Together, these findings reveal a previously unrecognized loss of supportive capacity in pathological MSCs that hampers NK-cell fitness. Therapeutic approaches that bolster mitochondrial resilience in NK cells may help counteract this microenvironment-induced impairment and strengthen immune surveillance in MDS and sAML.
    DOI:  https://doi.org/10.1038/s41375-026-03172-1
  5. Blood. 2026 Nov 12. pii: blood.2026033948. [Epub ahead of print]
      Myeloproliferative neoplasms (MPNs) arise from and are sustained by hematopoietic stem cells (HSCs) that acquire a driver mutation. Existing therapies fail to eliminate MPN HSCs, leaving allogeneic HSC transplantation (HSCT) as the only curative option. However, allogeneic HSCT non-selectively ablates both healthy and MPN HSCs, requiring donor stem-cell replacement and risking serious toxicities and death. MPN driver mutations in calreticulin (CALRmut) generate a shared C-terminal neopeptide unique to MPN cells that must be displayed at the cell surface in complex with the thrombopoietin receptor MPL to drive oncogenic signaling. These features make CALRmut an attractive target for selective immunotherapy. However, it is unknown whether MPN HSCs consistently display surface CALRmut to enable selective elimination in vivo via CALRmut targeting. We generated hAB2, a high-affinity CALRmut-specific humanized antibody, to use as the binding domain for chimeric antigen receptor (CAR)-T cells. We show that functional murine and human MPN HSCs express surface CALRmut that is reliably detected by AB2 in vitro and in vivo. We developed an MPN patient-derived tumor xenograft (PDTX) model to enable rigorous testing of human MPN HSC-directed therapies in vivo. hAB2 CAR-T cells selectively eliminate CALRmut MPN HSCs in PDTX, eradicating all detectable MPN-propagating function in serial transplantation assays, while preserving co-existing normal human and host hematopoiesis. These findings establish cell-surface CALRmut display as a therapeutically exploitable feature of MPN HSCs and support the feasibility of CALRmut-targeted, transplant-free immunotherapies with curative intent for CALRmut MPNs.
    DOI:  https://doi.org/10.1182/blood.2026033948
  6. Am J Hematol. 2026 Nov 13.
      
    Keywords:  GLP‐1 receptor agonists; leukemia; lymphoma; myelodysplastic; myeloma; myeloproliferative
    DOI:  https://doi.org/10.1002/ajh.70552
  7. Nature. 2026 Nov 11.
      Somatic evolution in ageing tissues underlies many cancers1,2. However, our quantitative understanding of the rules governing this pre-cancerous evolution remains incomplete. Here we exploit a unique collection of serial blood samples3, collected annually for up to a decade and beginning as early as 15 years before diagnosis of acute myeloid leukaemia, to provide a quantitative description of pre-cancerous evolutionary dynamics. Using deep duplex sequencing and evolutionary theory, we quantify the acquisition ages and fitness effects of the key driver events in acute myeloid leukaemia development. The first driver mutations are typically acquired in the first few decades of life, when the blood remains highly polyclonal. These early slow-growing clones subsequently acquire multiple further driver mutations that confer selective advantages up to 100-fold larger than the early drivers. These faster-growing clones harbouring multiple driver mutations can cause complete somatic sweeps of the blood decades before diagnosis, a feature strongly associated with future acute myeloid leukaemia. Our data show that the clonal dynamics of blood are consistent with a set of remarkably simple evolutionary rules that strike a balance between chance and determinism.
    DOI:  https://doi.org/10.1038/s41586-026-11269-x
  8. J Clin Oncol. 2026 Nov 13. JCO2600899
    German CML Study Group
       PURPOSE: To compare standard-dose dasatinib 100 mg once daily with reduced-dose using a weekend drug holiday to improve tolerability for patients with chronic myeloid leukemia (CML).
    PATIENTS AND METHODS: Patients with chronic phase CML (CP-CML) were randomly assigned to either receive standard-of-care dasatinib 100 mg once daily or an intermittent dasatinib schedule (5 days on, 2 days [weekend] off) in a prospective multicenter phase III trial. Achievement of major molecular remission (MMR) at 24 months and a newly developed cumulative toxicity score were coprimary end points.
    RESULTS: Of 289 eligible patients, 147 were assigned to standard-of-care dasatinib and 142 to intermittent dosing. Eighty percent of patients received first-line treatment (n = 232). In the standard arm, 105 of 130 patients (81% [95% CI, 74% to 88%) achieved MMR at 24 months compared with 101 of 130 patients (78% [95% CI, 71% to 85%]) in the experimental arm resulting in noninferiority within the prespecified noninferiority margin of 15% (P = .009). Among second- or later-line patients, MMR at 24 months was 24% lower, failing noninferiority. Comparison of grade 2-4 toxicities revealed no significant difference between the treatment arms. However, a post hoc analysis of toxicities of special interest (pleural effusion/pericardial effusion) showed 21 of 130 patients (16%) in the standard arm versus 10 of 125 (8%) patients in the experimental arm (P = .0464). Consistently, health-related quality of life improved mainly in first-line patients, with more favorable outcomes in the experimental arm.
    CONCLUSION: Intermittent dasatinib dosing with weekend treatment holidays in patients with CP-CML is noninferior to continuous dosing with respect to MMR at 24 months, at least in the first-line setting. The incidence of pleural or pericardial effusion appears to be reduced compared with standard-of-care continuous dosing.
    DOI:  https://doi.org/10.1200/JCO-26-00899
  9. Blood. 2026 Nov 10. pii: blood.2026034088. [Epub ahead of print]
      Anemia is a prevalent but poorly understood complication of diabetes mellitus. Here, we identify orphan nuclear receptor Nur77 as a critical suppressor of diabetic anemia. Nur77 expression was downregulated in hematopoietic stem and progenitor cells (HSPCs) from diabetic patients with anemia. In multiple diabetic mouse models, knockout of Nur77 induced anemia, a phenotype recapitulated by bone marrow transplantation. Mechanistically, Nur77 functioned as a transcriptional repressor in HSPCs, whose deficiency, together with diabetes-associated epigenetic modifications, enhanced chromatin accessibility and expression of genes involved in myeloid leukocyte differentiation. Consequently, this led to myeloid leukocyte-biased differentiation of HSPCs at the expense of erythroid lineage. Pharmacological upregulation of Nur77 with its agonist cytosporone B (Csn-B) effectively prevented anemia in diabetic mice. Clinically, Nur77 levels in HSPCs of diabetic patient negatively correlated with anemia occurrence. Collectively, our findings reveal a novel Nur77-mediated pathway in diabetic anemia pathogenesis and propose Nur77 as a new therapeutic target.
    DOI:  https://doi.org/10.1182/blood.2026034088
  10. Blood. 2026 Nov 12. pii: blood.2026036096. [Epub ahead of print]
      The optimal reduced-intensity conditioning (RIC) regimen for older patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) undergoing allogeneic hematopoietic stem cell transplantation (AHCT) remains undefined. We utilized CIBMTR registry data (2013-2022) to compare five common fludarabine-based regimens in 11,731 patients aged ≥50 years: fludarabine combined with 2 days of busulfan (FB2), melphalan 100 mg/m² (FM100), melphalan 140 mg/m² (FM140), or 2 Gy TBI with (FCT) or without (FT) cyclophosphamide. Using propensity score inverse probability weighting and Bayesian Additive Regression Trees (BART), we found that Fludarabine-melphalan (FM) regimens demonstrated superior long-term survival. Although FM140, FCT, and FT showed higher early mortality (≤6 months) than FB2 (P=.036), both FM100 (HR 0.79) and FM140 (HR 0.77) achieved significantly better late (> 6 months) overall survival (OS), outperforming all other regimens (P<.0001). In the 2019-2022 cohort, FM100, FM140, and FCT provided improved disease-free survival (DFS) relative to FB2. Specifically, FM100 yielded superior DFS compared to FCT (P=0.002) and FT (P=0.007). FM-based conditioning consistently resulted in lower relapse rates (P<.0001) and improved late GVHD-free/relapse-free survival. While FM regimens faced higher early non-relapse mortality (NRM), this impact did not persist beyond 6 months. BART analysis confirmed that these survival and relapse benefits remained robust across various patient comorbidities. In conclusion, FM100 and FM140 provide superior long-term survival and DFS for older patients with AML/MDS by providing potent anti-leukemic activity that offsets higher early toxicity. These findings support FM-based RIC as the preferred conditioning platform for this population, regardless of baseline comorbidities.
    DOI:  https://doi.org/10.1182/blood.2026036096
  11. bioRxiv. 2026 Oct 21. pii: 2026.10.20.760526. [Epub ahead of print]
      Accumulation of oncometabolites promotes tumorigenesis, but it is not known if there are naturally occurring tumor suppressor metabolites whose deficiency within cancer-initiating cells causes cancer. Many leukemia patients are ascorbate deficient. Here we show that hematopoietic-specific ascorbate depletion in mice is sufficient to cause or promote leukemogenesis. Hematopoietic-specific ascorbate depletion promoted leukemogenesis by acting within leukemia initiating cells. Ascorbate depletion in myeloid leukemia expanded plasmacytoid dendritic cells, an effect mediated by the ascorbate molecular targets TET2 and TET3. Leukemia cells accumulated ascorbate as part of a tumor suppressor response to neoplastic proliferation that limited progression but depleted circulating ascorbate. Ascorbate restoration in mice with established leukemias extended survival. Hematopoietic-specific ascorbate depletion caused leukemia in collaboration with TET2 loss and was sufficient to cause leukemia with high penetrance even in the absence of other engineered mutations. These results identify ascorbate as a physiological tumor suppressor metabolite in blood cancers.
    DOI:  https://doi.org/10.64898/2026.10.20.760526
  12. Br J Haematol. 2026 Nov 11.
      Nucleophosmin 1 (NPM1) mutations are found in around one third of all acute myeloid leukaemias (AMLs). However, little is known about the clinical role of the rare, non-A NPM1 variants. Sangiorgio et al. showed that rare variants shared a similar molecular background and overall survival to the common type A, with FMS-like tyrosine kinase 3 (FLT3) status as the main determinant of outcome. Commentary on: Sangiorgio et al. Rare variants of NPM1 mutations share a similar molecular background to the common NPM1 type A variant and are associated with similar survival in adults with acute myeloid leukaemia. Br J Haematol 2026 (Online ahead of print). doi: 10.1182/blood-2024-202884.
    Keywords:   FLT3 ; NPM1 ; AML
    DOI:  https://doi.org/10.1111/bjh.70954
  13. Blood Adv. 2026 Nov 10. pii: bloodadvances.2026021062. [Epub ahead of print]
      The aim was to characterize longitudinal JAK2V617F (JAK2) variant allele frequency (VAF) trajectories in individuals without MPN undergoing active surveillance, and to assess whether MPN can be detected at an earlier stage, resulting in lower clonal burden and less bone marrow fibrosis. In the Danish General Suburban Population Study (N=19,958, 2010-2013), we used retrospective measurement of JAK2 on biobanked samples in 2016-2017 and identified 92 JAK2-positive individuals with VAF≥1% that were without MPN at baseline in 2010-2013. Of these, 20 were diagnosed with MPN by clinical referral between 2010-2018. The remaining 72 were reinvited for active MPN surveillance (2018-2026), of whom 61 are included in the present study. Longitudinal JAK2 VAF was quantified using droplet digital PCR, and mixed-effects models were used to estimate clonal growth and blood cell trajectories. Median follow-up to MPN diagnosis was 7.4 years. Referral-diagnosed MPN cases exhibited a relative clonal growth rate of 34.3% per year (p<0.001). Among the 61 undergoing surveillance, 20 were diagnosed with MPN, exhibiting a relative clonal growth rate of 12.7% per year (p=0.003), whereas the remaining 41 did not develop MPN nor showed VAF progression (p=0.628). Within-individual and between-individual variance in VAF was 4.9% and 95.1%, respectively. Platelet counts increased 10.3×10⁹/L/year for surveillance-detected MPN and 44.5×10⁹/L/year for referral-diagnosed MPN. Surveillance-detected MPN had lower VAF at diagnosis (median 13.0% vs 41.3%) and less bone marrow fibrosis (grade 0: 80% vs 15%) than referral-diagnosed MPN. Active surveillance detects MPN with lower clonal burden and less bone marrow fibrosis.
    DOI:  https://doi.org/10.1182/bloodadvances.2026021062
  14. Br J Haematol. 2026 Nov 09.
      Juvenile myelomonocytic leukaemia (JMML) is a childhood myeloid malignancy driven by RAS (rat sarcoma viral oncogene homolog) pathway mutations, characterized by myeloid cell accumulation and organ infiltration. We investigated how clonal macrophage polarization, phagocytic function and CD47 (cluster of differentiation 47) expression contribute to immune dysregulation. Human PTPN11 (protein tyrosine phosphatase non-receptor type 11) -mutated JMML spleens exhibited higher M1-like macrophage levels than KRAS (KRAS proto-oncogene, GTPase)-mutated cases or controls. Both human JMML macrophages and murine cells from Mx-Cre;Ptpn11D61Y/+ mice retained phagocytic activity, with M1-like cells being the most active. CD47, a 'don't eat me' signal, was upregulated in human and murine JMML cells; its blockade enhanced in vitro phagocytosis. In a patient-derived xenograft model, the CD47 inhibitor magrolimab reduced leukaemia burden in the spleen but not the bone marrow. No synergy was observed between magrolimab and azacitidine. These findings demonstrate that clonal JMML macrophages retain phagocytic activity and contribute to an inflammatory phenotype. While CD47 blockade shows limited therapeutic potential, this study clarifies the interplay between macrophage polarization, immune evasion and inflammation, providing a basis for future JMML strategies.
    Keywords:  CD47; JMML; haematology; macrophages; phagocytosis
    DOI:  https://doi.org/10.1111/bjh.70871
  15. Cell Death Dis. 2026 Aug 12. pii: 951. [Epub ahead of print]17(1):
      Disease persistence and resistance remain major challenges in chronic myeloid leukemia (CML). We evaluated pharmacological SOS1 inhibition with BI-3406, alone or in combination with BCR::ABL1 tyrosine-kinase inhibitors (TKI), across complementary preclinical models. In p210BCR/ABL transgenic mice, BI-3406 plus imatinib was well-tolerated, markedly prolonged survival, improved hematologic indices, reduced splenomegaly, and decreased bone-marrow LSK/hematopoietic stem and progenitor cells compared to either agent alone. In human CML cell lines and primary patient-derived bone-marrow cells, combined therapeutic treatments with BI-3406 and imatinib (standard of care BCR-ABL TKI) or next-generation TKIs showed strong synergistic suppression of cellular proliferation and increased apoptosis relative to single-agent treatment. Remarkably, drug combinations containing BI-3406 also restored TKI sensitivity to primary bone-marrow cell samples derived from a variety of CML patients that had been initially identified as clinically resistant to imatinib. Mechanistically, BI-3406 attenuated RAS/RAC-ERK/AKT signaling, while SOS1 knockdown phenocopied BI-3406-mediated imatinib sensitization, supporting an on-target SOS1-dependent therapeutic effect. Upregulation of the membrane transport protein SLC22A4 following combination treatment may contribute to the rescued TKI sensitivity but is probably not the sole underlying mechanism as BI-3406+imatinib retained strong synergistic activity despite SLC22A4 knockdown. Comparison of the transcriptomic profiles revealed that the combined BI-3406+imatinib drug regimen triggered the strongest repression of oncogenic, metabolic and stemness-associated transcriptional programs in treated CML cells. Consistently, serial replating MethoCult assays functionally confirmed the impairment of clonogenic self-renewal capacity and the depletion of murine LSK and human Lin⁻CD34⁺CD38⁻ stem/progenitor-enriched compartments after dual SOS1 and BCR::ABL1 inhibition. Our data support SOS1 targeting as a rational therapeutic strategy to potentiate TKI efficacy, impair CML stem/progenitor self-renewal, and restore drug responsiveness in clinically relevant TKI-resistant settings.
    DOI:  https://doi.org/10.1038/s41419-026-09170-6
  16. Hemasphere. 2026 Nov;10(11): e70523
      DNA hypomethylating agents (HMAs) such as 5-azacytidine (5-AZA) are a cornerstone in the treatment of acute myeloid leukemia (AML), but development of resistance represents a major clinical challenge. Apart from epigenetic reprogramming of malignant cell clones, therapy with HMA is increasingly recognized to facilitate antineoplastic immunity, yet the relevance of these molecular mechanisms in AML remains poorly defined. Here, we show that AML cell-intrinsic sensing of aberrant RNA via the innate receptor system retinoic acid-inducible gene I (RIG-I)/mitochondrial antiviral-signaling protein (MAVS) is essential for the therapeutic activity of HMAs. In human and murine AML cell lines, HMA treatment induced robust RIG-I/MAVS pathway activation and subsequent Type I interferon (IFN-I) release. HMA enhanced transcriptional activity of endogenous retroviral (ERV) elements that readily bound to the RIG-I receptor. Analysis of a small series of patient samples linked treatment response to elevated gene expression of ERV and RIG-I/MAVS pathway components in CD34+ cells including AML blasts. AML-intrinsic genetic ablation of MAVS or RIG-I abrogated the HMA treatment effects in mice by interfering with host IFN-I signaling and subsequent expansion and accumulation of activated T cells. Acquired HMA resistance was associated with ERV suppression and blunted RIG-I/MAVS signaling. Treatment with all-trans retinoic acid (ATRA) restored RIG-I pathway activity and antileukemic response in mice bearing HMA-resistant AML. Our findings not only delineate a critical link between epigenetic modulation and innate immune activation in AML but also provide a rationale for targeting the RIG-I/MAVS RNA-sensing pathway to enhance antileukemic immunity and bypass epigenetic resistance to HMA.
    DOI:  https://doi.org/10.1002/hem3.70523
  17. Nat Med. 2026 Nov;32(11): 4234-4243
      Allogeneic hematopoietic cell transplantation can cure certain hematological disorders but has many complications. In retrospective studies, low gut microbiome diversity is associated with adverse clinical outcomes. In 2023, the Blood and Marrow Transplant Clinical Trials Network 1703 randomized phase 3 trial demonstrated the superiority of post-transplant cyclophosphamide (PTCy) and mycophenolate mofetil to tacrolimus and methotrexate (Tac/MTX) for graft-versus-host disease prophylaxis in participants with hematological malignancies undergoing allogeneic hematopoietic cell transplantation. Here we report on the microbiome-focused companion study to 1703, Blood and Marrow Transplant Clinical Trials Network 1801, which coenrolled participants and shared trial registration. The primary endpoint was association between microbiome diversity at neutrophil engraftment and non-relapse mortality after 1 year; secondary endpoints included associations with other clinical outcomes and with baseline microbiome diversity. Based on 2575 longitudinally collected stool samples from 304 participants (Tac/MTX n = 147, PTCy n = 157), no association between engraftment microbiome diversity and non-relapse mortality was observed (P = 0.314), not meeting the primary endpoint. Lower baseline microbiome diversity was associated with shorter overall survival (P = 0.007). Safety data were reported in the original 1703 publication. In exploratory analyses, microbiome diversity and absolute microbial load were lower in PTCy compared to Tac/MTX on days 14-28 following HCT, independent of non-prophylaxis antibiotics exposure. Microbial domination events, when a single species exceeds 30% relative abundance, did not differ significantly between study arms and reflected both pathogen blooms and less severe disruptions of the microbial community. Clostridium scindens and secondary bile-acid metabolism pathways were less prevalent in PTCy than in Tac/MTX following HCT. In summary, we find prophylaxis regimens likely exert independent effects on both the microbiome and immune compartments and can also impact their interaction. Understanding whether and how microbiome-targeted interventions might improve transplant outcomes will therefore require careful disentangling of these effects within each specific treatment context. ClinicalTrials.gov identifier: NCT03959241 .
    DOI:  https://doi.org/10.1038/s41591-026-04712-z
  18. Haematologica. 2026 Nov 12.
      Clonal hematopoiesis (CH) in long-term survivors of allogeneic hematopoietic cell transplant (HCT) remains largely understudied. Using targeted sequencing, we analyzed peripheral blood samples from 101 patients who survived without relapse for more than 10 years after HCT. The median interval from HCT to sample collection was 13.8 years (range, 10.0-29.8 years). Thirty-six CHs with ≥2% variant allele frequency were detected in 29 patients (28.7%). Complete blood count did not differ according to CH status. Multivariable analysis showed donor age at sampling (odds ratio [OR] 1.06, 95% confidence interval [CI] 1.00-1.12), patients who underwent HCT for chronic myeloid leukemia (CML; OR 7.13, 95% CI 1.38-36.8), and moderate/severe chronic graft-versushost disease at sampling (OR 5.49, 95% CI 1.05-28.7) were significantly associated with CH. Donor age at sampling was significantly higher in patients with pathogenic CH than in those with variants of unknown significance or those without CH (median 56.5 vs 48.0 vs 47.0 years old, p=0.0077). After a median follow-up of 60.0 months after sampling, one patient with CML experienced relapse. Three-year Overall survival (94.2% vs. 92.9%, p=0.800) and cumulative incidence of second cancer (18.0% vs. 14.9%, p=0.410) after CH sampling were not associated with CH status. In conclusion, CH in HCT survivors is common and associated with donor age, transplantation for CML, and chronic graftversus-host disease.
    DOI:  https://doi.org/10.3324/haematol.2026.301340
  19. Leukemia. 2026 Nov 12.
      Third-generation tyrosine-kinase inhibitors (3G-TKIs), including olverembatinib and ponatinib, are effective in people with chronic myeloid leukemia (CML) failing prior TKIs, but many subjects still have poor responses and outcomes. The broader genomic and transcriptomic features associated with 3G-TKI prognosis remain incompletely defined. We interrogated genomic and transcriptomic data from 202 subjects receiving olverembatinib or ponatinib at baseline and during therapy. In penalized multi-variable analyses, the high-burden ASXL1 p.G646Wfs*12 (ASXL1G646Wfs*12) variant emerged as the most consistent genomic feature associated with inferior responses and outcomes; additional lower-frequency variants, including RUNX1, IKZF1, PHF6, SETBP1 and GATA2 variants, were also associated with responses and/or outcomes. Longitudinal genomic analyses showed that ABL1 variants frequently decreased during 3G-TKI therapy, whereas persistent, emerging or expanding non-ABL1 variant clones were enriched in resistant subjects, suggesting a shift toward BCR::ABL1-independent clonal evolution in later-line resistance. Transcriptomic analyses identified three distinct gene expression profiles (GEPs) based clusters with different prognoses. Favorable prognosis was associated with lower leukemic stemness and more immune-active transcriptional features, whereas poor prognosis was characterized by stemness- and proliferation-dominant, immune-suppressed states. These findings identify genomic and transcriptomic features associated with 3G-TKI prognosis and provide a potential framework for molecular risk stratification in later-line CML that requires independent validation.
    DOI:  https://doi.org/10.1038/s41375-026-03182-z
  20. JCI Insight. 2026 Nov 10. pii: e208950. [Epub ahead of print]
      Essential thrombocythemia (ET) and myelofibrosis (MF) are myeloproliferative neoplasms (MPN) that can result from heterozygous or homozygous mutations in the calreticulin (CRT) gene (CALR). Mutant CRT binds to the thrombopoietin receptor to induce signaling that drives ET and MF. CRT is also a chaperone for the assembly of the highly polymorphic human leukocyte antigen (HLA) class I molecules. The effects of heterozygous versus homozygous MPN CALR mutations on the expression of HLA class I variants are unknown. To assess mutant CRT-induced changes to HLA class I expression, we generated CRISPR-based mutant CALR knock-in cell lines and CALR-knockout cell lines reconstituted with wild-type or MPN mutant CALR and also undertook measurements in MPN patient platelets and monocytes. Collectively, our findings indicate that heterozygous CALR mutations preserve HLA class I surface expression, whereas full loss of wild-type CRT results in marked, allele-dependent reductions in HLA class I expression, which are rescued by wild-type CRT but not MPN mutants. Reduced expression of CRT-dependent HLA class I in cells lacking a functional CRT induces natural killer (NK) cell activation. These studies identify specific HLA class I alleles and homozygous CALR mutations as prerequisites for low HLA class I expression in MPN.
    Keywords:  Immunology; MHC class 1; NK cells; Oncology
    DOI:  https://doi.org/10.1172/jci.insight.208950
  21. bioRxiv. 2026 Oct 23. pii: 2026.10.20.760390. [Epub ahead of print]
      Hematopoietic stem cells (HSCs) reside in specialized bone marrow microenvironments, termed niches, which regulate self-renewal and differentiation through local support programs. Although multiple anatomically distinct niches with unique cellular compositions have been described, it remains unclear to what degree these niches differentially shape HSC fate. In parallel, hematopoietic output is modulated with age, yet it remains unclear if this shift in HSC fate is driven by niche-specific modifications. To address these questions, we applied Multiplexed Error Robust Fluorescence in situ Hybridization to jointly define the cellular and spatial organization of the femoral marrow in young and aged mice. We find that while HSC niches are anatomically and compositionally distinct, stem cell lineage priming is not strongly associated with niche identity consistent with our demonstration that fate-shaping signals are provided redundantly across niches. Moreover, we find that while aging remodels the cellular composition of the marrow, reshapes cellular expression, and alters hematopoietic differentiation, HSC niches are preserved, and HSC fate remains niche agnostic. Together these findings separate anatomical niche identity from early HSC fate decisions and are consistent with a model in which hematopoietic support is distributed across different niche locations rather than partitioned among discrete sites.
    DOI:  https://doi.org/10.64898/2026.10.20.760390
  22. Blood. 2026 Nov 10. pii: blood.2026035185. [Epub ahead of print]
      Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy characterized by leukemic blasts with frequent cutaneous involvement and high CD123 expression. Pivekimab sunirine, an anti-CD123 antibody-drug conjugate with a DNA-alkylating payload, was approved by the United States Food and Drug Administration on May 27, 2026, for adults with BPDCN based on the CADENZA study. We review its mechanism, clinical efficacy, toxicity, and role in the evolving treatment landscape for BPDCN and AML.
    DOI:  https://doi.org/10.1182/blood.2026035185